دیدگاه جهانی در مورد تشخیص و درمان سندرم تخمدان پلی‌کیستیک: یک مطالعه مروری روایتی از دستورالعمل‌های بالینی مختلف

نوع مقاله : مروری

نویسندگان

1 کارشناس ارشد مامایی، پژوهشگاه رویان، پژوهشکده زیست‌شناسی و علوم پزشکی تولید مثل جهاد دانشگاهی، مرکز تحقیقات پزشکی تولید مثل، گروه اندوکرینولوژی و ناباروری زنان، تهران، ایران.

2 استادیار زیست‌شناسی، دانشکده علوم پایه، دانشگاه شاهد، تهران، ایران.

3 استادیار گروه زنان و زایمان، فلوشیپ نازایی، پژوهشگاه رویان، پژوهشکده زیست‌شناسی و علوم پزشکی تولید مثل جهاد دانشگاهی، مرکز تحقیقات پزشکی تولیدمثل، گروه تصویربرداری تولید مثل، تهران، ایران.

4 دکترای علوم مدیریت، پژوهشگاه رویان، پژوهشکده زیست‌شناسی و علوم پزشکی تولید مثل جهاد دانشگاهی، مرکز تحقیقات پزشکی تولید مثل، گروه تصویربرداری تولید مثل تهران، تهران، ایران.

5 استادیار غدد درون‌ریز و متابولیسم، پژوهشگاه رویان، پژوهشکده زیست‌شناسی و علوم پزشکی تولید مثل جهاد دانشگاهی، مرکز تحقیقات پزشکی تولید مثل، گروه آندرولوژی، تهران، ایران.

6 دکتری تخصصی مهندسی بافت، گروه پژوهشی لیزر پزشکی، مرکز تحقیقات لیزر در پزشکی، پژوهشکده یارا، جهاد دانشگاهی واحد علوم پزشکی تهران، تهران، ایران.

7 دانشیار گروه آناتومی، پژوهشگاه رویان، پژوهشکده زیست‌شناسی و علوم پزشکی تولید مثل جهاد دانشگاهی، مرکز تحقیقات پزشکی تولید مثل، گروه جنین‌شناسی، تهران، ایران.

10.22038/ijogi.2025.85489.6336

چکیده

مقدمه: سندرم تخمدان پلی‌کیستیک (PCOS) یکی از شایع‌ترین اختلالات غدد درون‌ریز در زنان است که تشخیص و مدیریت آن در کشورها و جمعیت‌های مختلف با تفاوت‌هایی همراه است. هدف این مطالعه، مرور روایی دستورالعمل‌های کلیدی ارائه‌ شده توسط جوامع علمی معتبر از جمله آمریکا، اروپا، استرالیا و چین است.
روش‌کار: در این مطالعه مروری، جستجوی سیستماتیک در پایگاه‌های داده PubMed، Science Direct، Scopus و موتور جستجوی Google Scholar انجام شد. پس از بررسی منابع، چندین گایدلاین بالینی معتبر برای تحلیل نهایی انتخاب شدند. کیفیت این دستورالعمل‌ها با استفاده از ابزارهای معتبر ارزیابی و داده‌ها به‌صورت توصیفی تحلیل گردید.
یافته­ها: با وجود اشتراکات در بسیاری از توصیه‌ها، تفاوت‌های قابل توجهی در آستانه‌های تشخیصی پارامترهای بالینی و بیوشیمیایی و نیز درمان‌های خط اول مشاهده شد. این تفاوت‌ها اغلب ناشی از شرایط جمعیتی، فرهنگی و ساختار نظام‌های سلامت در هر کشور هستند.
نتیجه ­گیری: با توجه به تفاوت‌های شناسایی ‌شده در دستورالعمل‌های بین‌المللی، یافته‌های این مطالعه ضرورت تدوین دستورالعمل‌های بومی متناسب با نیازهای جمعیت ایرانی را برجسته می‌سازد. تشکیل کارگروه‌های تخصصی با بهره‌گیری از دستورالعمل‌‌های بین‌المللی و توجه به شرایط محلی، می‌تواند کیفیت مراقبت از بیماران، به‌ویژه نوجوانان را ارتقاء داده و از عوارض بلندمدت مرتبط با PCOSپیشگیری کند. بازنگری منظم و آموزش‌های مستمر نیز در بهبود اثربخشی خدمات درمانی نقش کلیدی دارند.

کلیدواژه‌ها

موضوعات

عنوان مقاله [English]

Global Perspective on the Diagnosis and Treatment of Polycystic Ovary Syndrome: A Narrative Review of Different Clinical Guidelines

نویسندگان [English]

  • Arezoo Arabipoor 1
  • Fatemeh Hasani 2
  • Maryam Hafezi 3
  • ,Shohreh Irani 4
  • Roya Hosseini 5
  • Nahid Nasiri 6
  • Poopak Eftekhari Yazdi, 7
1 M.Sc. of Midwifery, Royan Institute, ACECR, Reproductive Biomedicine Research Center, Department of Endocrinology and Female Infertility, Tehran, Iran.
2 Assistant Professor, Department of Biology, Faculty of Basic Sciences, Shahed University, Tehran, Iran.
3 Assistant Professor, Department of Obstetrics and Gynecology, Fellowship of Infertility, ACECR, Royan Institute, Reproductive Biomedicine Research Center, Department of Reproductive Imaging, Reproductive Imaging, Tehran, Iran.
4 PhD in Management Sciences, Royan Institute, ACECR, Reproductive Biomedicine Research Center, Department of Reproductive Imaging, Tehran, Iran.
5 Assistant Professor, Department of Endocrine and Metabolism, Royan Institute, ACECR, Reproductive Biomedicine Research Center, Department of Andrology, Tehran, Iran.
6 PhD in Tissue Engineering, Medical Laser Research Group, Laser Research Center in Medicine, YARA Research Institute, Academic Center for Education, Culture and Research (ACECR), Tehran University of Medical Sciences Branch, Tehran, Iran.
7 Associate Professor, Department of Anatomy, Royan Institute, ACECR, Reproductive Biomedicine Research Center, Department of Embryology, Tehran, Iran.
چکیده [English]

Introduction: Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women, with variations in its diagnosis and management across different countries and populations. This study was performed with aims to conduct a narrative review of key clinical guidelines issued by reputable scientific societies, including United States, Europe, Australia, and China.
Methods: In this review study, a systematic search was performed across PubMed, ScienceDirect, Scopus databases, and the Google Scholar search engine. Following resource evaluation, several authoritative clinical guidelines were selected for final analysis. The quality of these guidelines was assessed using validated tools, and data were analyzed descriptively.
Results: While many recommendations showed consensus, significant variations were observed in diagnostic thresholds for clinical and biochemical parameters, as well as in first-line treatment approaches. These differences primarily stem from demographic characteristics, cultural factors, and healthcare system structures in each country.
Conclusion: Given the identified disparities among international guidelines, this study highlights the necessity of developing localized guidelines tailored to the needs of the Iranian population. Establishing specialized task forces that incorporate international guidelines while considering local conditions could enhance patient care quality - particularly for adolescents - and prevent long-term PCOS-related complications. Regular updates and continuous education programs also play a pivotal role in improving the effectiveness of therapeutic services.

کلیدواژه‌ها [English]

  • Diagnosis
  • Polycystic Ovary Syndrome
  • Practice Guideline
  • Therapeutics

مراجع

  1. Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Human reproduction 2016; 31(12):2841-55.
  2. Zhuang J, Liu Y, Xu L, Liu X, Zhou L, Tang L, et al. Prevalence of the polycystic ovary syndrome in female residents of Chengdu, China. Gynecologic and obstetric investigation 2014; 77(4):217-23.
  3. Sayehmiri F, Kiani F, Sayehmiri K, Maleki F, Ahmadi M, Shohani M. Prevalence of polycystic ovary syndrome in Iranian women: a systematic review and meta-analysis. The Iranian Journal of Obstetrics, Gynecology and infertility 2014; 17(115):11-21.
  4. Mousavi M, Saei GN, Azizi F, Ramezani TF. Prevalence of Polycystic Ovary Syndrome and Risk Factors among Females with Diabetes: A Population-Based Study. Iranian Journal of Endocrinology & Metabolism 2023; 25(3):215-221
  5. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocrine reviews 2012; 33(6):981-1030.
  6. Tata B, Mimouni NE, Barbotin AL, Malone SA, Loyens A, Pigny P, et al. Elevated prenatal anti-Müllerian hormone reprograms the fetus and induces polycystic ovary syndrome in adulthood. Nature medicine 2018; 24(6):834-46.
  7. Nasiri N, Arabipoor A, Eftekhari-Yazdi P. The role of inflammation and oxidative stress in the etiology of polycystic ovary syndrome: a review article. Iranian Journal of Obstetrics, Gynecology and Infertility 2022; 25(11):73-87.
  8. Moran LJ, Norman RJ, Teede HJ. Metabolic risk in PCOS: phenotype and adiposity impact. Trends in Endocrinology & Metabolism 2015; 26(3):136-43.
  9. Teede HJ, Joham AE, Paul E, Moran LJ, Loxton D, Jolley D, et al. Longitudinal weight gain in women identified with polycystic ovary syndrome: results of an observational study in young women. Obesity 2013; 21(8):1526-32.
  10. Dokras A, Stener-Victorin E, Yildiz BO, Li R, Ottey S, Shah D, et al. Androgen Excess-Polycystic Ovary Syndrome Society: position statement on depression, anxiety, quality of life, and eating disorders in polycystic ovary syndrome. Fertility and sterility 2018; 109(5):888-99.
  11. Al Wattar BH, Bueno A, Martin MG, Ibáñez NC, Harasani K, Garad R, et al. Harmonizing research outcomes for polycystic ovary syndrome (HARP), a marathon not a sprint: current challenges and future research need. Human Reproduction 2021; 36(3):523-8.
  12. Al Wattar BH, Teede H, Garad R, Franks S, Balen A, Bhide P, et al. Harmonising research outcomes for polycystic ovary syndrome: an international multi-stakeholder core outcome set. Human Reproduction 2020; 35(2):404-12.
  13. Al Wattar BH, Fisher M, Bevington L, Talaulikar V, Davies M, Conway G, et al. Clinical practice guidelines on the diagnosis and management of polycystic ovary syndrome: a systematic review and quality assessment study. The Journal of Clinical Endocrinology & Metabolism 2021; 106(8):2436-46.
  14. Jalilian A, Kiani F, Sayehmiri F, Sayehmiri K, Khodaee Z, Akbari M. Prevalence of polycystic ovary syndrome and its associated complications in Iranian women: A meta-analysis. Iranian journal of reproductive medicine 2015; 13(10):591.
  15. Teede HJ, Tay CT, Laven JJ, Dokras A, Moran LJ, Piltonen TT, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. European journal of endocrinology 2023; 189(2):G43-64.
  16. Forslund M, Melin J, Stener‐Victorin E, Hirschberg AL, Teede H, Vanky E, et al. International evidence‐based guideline on assessment and management of PCOS—A nordic perspective. Acta obstetricia et gynecologica Scandinavica 2024; 103(1):7-12.
  17. Chen ZJ, Zhang YW, Liu JY. Diagnosis criteria for polycystic ovary syndrome. Natl Health Fam Plan Commission China 2011; 330:1-7.
  18. Teede HJ, Misso ML, Boyle JA, Garad RM, McAllister V, Downes L, et al. Translation and implementation of the Australian‐led PCOS guideline: clinical summary and translation resources from the International Evidence‐based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Medical journal of Australia 2018; 209:S3-8.
  19. Malik S, Jain K, Talwar P, Prasad S, Dhorepatil B, Devi G, et al. Management of polycystic ovary syndrome in India. Fertility Science and Research 2014; 1(1):23-43.
  20. Witchel SF, Oberfield S, Rosenfield RL, Codner E, Bonny A, Ibáñez L, et al. The diagnosis of polycystic ovary syndrome during adolescence. Hormone research in paediatrics 2015; 83(6):376-89.
  21. Ibáñez L, Oberfield SE, Witchel S, Auchus RJ, Chang RJ, Codner E, et al. An international consortium update: pathophysiology, diagnosis, and treatment of polycystic ovarian syndrome in adolescence. Hormone research in paediatrics 2017; 88(6):371-95.
  22. Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Human reproduction 2008; 23(3):462-77.
  23. Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertility and sterility 2012; 97(1):28-38.
  24. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism 2013; 98(12):4565-92.
  25. Dewailly D, Lujan ME, Carmina E, Cedars MI, Laven J, Norman RJ, et al. Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society. Human reproduction update 2014; 20(3):334-52.
  26. Teede HJ, Mlsso ML, Deeks AA, Moran LJ, Stuckey BG, Wong JL, et al. Assessment and management of polycystic ovary syndrome: summary of an evidence-based guideline. Medical Journal of Australia 2011.
  27. Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human reproduction 2018; 33(9):1602-18.
  28. Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E. American Association of Clinical Endocrinologists, American College of Endocrinology, and androgen excess and PCOS society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome-part 1. Endocrine Practice 2015; 21(11):1291-300.
  29. Peña AS, Witchel SF, Hoeger KM, Oberfield SE, Vogiatzi MG, Misso M, et al. Adolescent polycystic ovary syndrome according to the international evidence-based guideline. BMC medicine 2020; 18(1):72.
  30. Balen AH, Laven JS, Tan SL, Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Human reproduction update 2003; 9(6):505-14.
  31. Lujan ME, Jarrett BY, Brooks ED, Reines JK, Peppin AK, Muhn N, et al. Updated ultrasound criteria for polycystic ovary syndrome: reliable thresholds for elevated follicle population and ovarian volume. Human reproduction 2013; 28(5):1361-8.
  32. Li R, Zhang Q, Yang D, Li S, Lu S, Wu X, et al. Prevalence of polycystic ovary syndrome in women in China: a large community-based study. Human reproduction 2013; 28(9):2562-9.
  33. Cui L, Zhao H, Zhang B, Qu Z, Liu J, Liang X, et al. Genotype–phenotype correlations of PCOS susceptibility SNPs identified by GWAS in a large cohort of Han Chinese women. Human Reproduction 2013; 28(2):538-44.
  34. Merkin SS, Phy JL, Sites CK, Yang D. Environmental determinants of polycystic ovary syndrome. Fertility and sterility 2016; 106(1):16-24.
  35. Wang FF, Pan JX, Wu Y, Zhu YH, Hardiman PJ, Qu F. American, European, and Chinese practice guidelines or consensuses of polycystic ovary syndrome: a comparative analysis. Journal of Zhejiang University-Science B 2018; 19(5):354-63.
  36. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertility and sterility 2009; 91(2):456-88.
  37. Peña AS, Codner E, Witchel S. Criteria for diagnosis of polycystic ovary syndrome during adolescence: literature review. Diagnostics 2022; 12(8):1931.
  38. Saei GN, Amiri M, Ramezani TF. The Evolutionary Approach for Diagnostic Criteria of Polycystic Ovary Syndrome in Adolescents: a Review. Iranian Journal of Endocrinology & Metabolism 2019; 21(4):253-265.
  39. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81(1):19-25.
  40. Ahmadi A. Prevalence of symptoms of polycystic ovary syndrome and some Associated factors in medical students. Journal of Babol University of Medical Sciences 2022; 24(1):215-23.
  41. Lim SS, Hutchison SK, Van Ryswyk E, Norman RJ, Teede HJ, Moran LJ. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews 2019(3).
  42. Ghaneei A, Jowkar A, Ghavam MR, Ghaneei ME. Cabergoline plus metformin therapy effects on menstrual irregularity and androgen system in polycystic ovary syndrome women with hyperprolactinemia. Iranian journal of reproductive medicine 2015; 13(2):93.
  43. Stabile G, Borrielli I, Artenisio AC, Bruno LM, Benvenga S, Giunta L, et al. Effects of the insulin sensitizer pioglitazone on menstrual irregularity, insulin resistance and hyperandrogenism in young women with polycystic ovary syndrome. Journal of pediatric and adolescent gynecology 2014; 27(3):177-82.
  44. Wu Y, Robinson N, Hardiman PJ, Taw MB, Zhou J, Wang FF, et al. Acupuncture for treating polycystic ovary syndrome: guidance for future randomized controlled trials. Journal of Zhejiang University-SCIENCE B 2016; 17(3):169-80.
  45. Qu F, Li R, Sun W, Lin G, Zhang R, Yang J, et al. Use of electroacupuncture and transcutaneous electrical acupoint stimulation in reproductive medicine: a group consensus. Journal of Zhejiang University-Science B 2017; 18(3):186-93.
  46. Forslund M, Melin J, Alesi S, Piltonen T, Romualdi D, Tay CT, et al. Combined oral contraceptive pill compared with no medical treatment in the management of polycystic ovary syndrome: a systematic review. Clinical endocrinology 2023; 99(1):79-91.
  47. Samimi M, Jamilian M, Ebrahimi FA, Rahimi M, Tajbakhsh B, Asemi Z. Expression of Concern: Oral carnitine supplementation reduces body weight and insulin resistance in women with polycystic ovary syndrome: a randomized, double‐blind, placebo‐controlled trial. Clinical endocrinology 2016; 84(6):851-7.
  48. Ashoush S, Abou‐Gamrah A, Bayoumy H, Othman N. Chromium picolinate reduces insulin resistance in polycystic ovary syndrome: Randomized controlled trial. Journal of Obstetrics and Gynaecology Research 2016; 42(3):279-85.
  49. Foroozanfard F, Jamilian M, Jafari Z, Khassaf A, Hosseini A, Khorammian H, et al. Effects of zinc supplementation on markers of insulin resistance and lipid profiles in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Experimental and clinical endocrinology & diabetes 2015; 123(04):215-20.
  50. Nandalike K, Agarwal C, Strauss T, Coupey SM, Isasi CR, Sin S, et al. Sleep and cardiometabolic function in obese adolescent girls with polycystic ovary syndrome. Sleep medicine 2012; 13(10):1307-12.
  51. Nidhi R, Padmalatha V, Nagarathna R, Ram A. Effect of a yoga program on glucose metabolism and blood lipid levels in adolescent girls with polycystic ovary syndrome. International Journal of Gynecology & Obstetrics 2012; 118(1):37-41.
  52. Amr N, Abdel-Rahim HE. The effect of chromium supplementation on polycystic ovary syndrome in adolescents. Journal of pediatric and adolescent gynecology 2015; 28(2):114-8.
  53. Tan S, Hahn S, Benson S, Janssen OE, Dietz T, Kimmig R, et al. Psychological implications of infertility in women with polycystic ovary syndrome. Human Reproduction 2008; 23(9):2064-71.
  54. McCook JG, Bailey BA, Williams SL, Anand S, Reame NE. Differential contributions of polycystic ovary syndrome (PCOS) manifestations to psychological symptoms. The journal of behavioral health services & research 2015; 42(3):383-94.
  55. Bazarganipour F, Ziaei S, Montazeri A, Foroozanfard F, Kazemnejad A, Faghihzadeh S. Psychological investigation in patients with polycystic ovary syndrome. Health and quality of life outcomes 2013; 11(1):141.
  56. Løvvik TS, Carlsen SM, Salvesen Ø, Steffensen B, Bixo M, Gómez-Real F, et al. Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial. The lancet Diabetes & endocrinology 2019; 7(4):256-66.
  57. Vanky E, Zahlsen K, Spigset O, Carlsen SM. Placental passage of metformin in women with polycystic ovary syndrome. Fertility and sterility 2005; 83(5):1575-8.
  58. Given JE, Loane M, Garne E, Addor MC, Bakker M, Bertaut-Nativel B, et al. Metformin exposure in first trimester of pregnancy and risk of all or specific congenital anomalies: exploratory case-control study. bmj 2018; 361.
  59. Hanem LG, Salvesen Ø, Juliusson PB, Carlsen SM, Nossum MC, Vaage MØ, et al. Intrauterine metformin exposure and offspring cardiometabolic risk factors (PedMet study): a 5–10 year follow-up of the PregMet randomised controlled trial. The Lancet Child & Adolescent Health 2019; 3(3):166-74.
مجله زنان، مامایی و نازایی ایران
دوره 28، شماره 8
آبان 1404
صفحه 68-83

فایل ها

هم رسانی

ارجاع به این مقاله

آمار